The lncRNA HMMR-AS1 promotes the malignant progression of ovarian cancer cells by regulating the miR-627-3p/PTN axis

Background Long non-coding RNAs (lncRNAs) are crucial regulators of ovarian cancer(OC), playing a significant role in malignant transformation and closely linked to poor prognosis. Therefore, it is crucial to investigate the impact of lncRNAs on the malignant biological behavior of ovarian cancer and to understand their underlying molecular mechanisms. Methods The binding sites of target genes were predicted through bioinformatics analysis, and gene expression levels were measured using qRT-PCR. The malignant biological behavior of cells was assessed through cell biological function assays. Gene targeting relationships were verified using a dual-luciferase reporter gene(DLRG) assay. Protein expression levels were analyzed using Western blotting. Results Hyaluronan-mediated motility receptor antisense RNA1(HMMR-AS1) expression is upregulated in ovarian cancer cells. Cell biological function experiments demonstrated that HMMR-AS1 promotes malignant biological behaviors in ovarian cancer cells. DLRG experiments demonstrated that HMMR-AS1 targets miR-627-3p, which in turn targets pleiotrophin(PTN). Furthermore, we discovered that HMMR-AS1 functions as a competing endogenous RNA (ceRNA) for miR-627-3p, regulating the expression of PTN and thereby promoting the malignant phenotypes of ovarian cancer cells. Conclusions In summary, our study indicates that lncRNA HMMR-AS1 is highly expressed in ovarian cancer and plays a carcinogenic role. Targeting the lncRNA HMMR-AS1 may offer a novel therapeutic strategy for treating ovarian cancer.